Considering aUC patients who progressed with PBC and ICIs, data from the EV-301 Phase III trial showed a benefit of EV, an ADC directed to nectin-4 (a cell-adhesion molecule expressed in UC) [28]. This evidence concerns the gene NECTIN4 and primary biliary cholangitis.